Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Income from Continuing Operations data on file, last reported at 4105000.0 in Q4 2025.

• On a quarterly basis, Income from Continuing Operations fell 126.78% year-over-year to 4105000.0 in Q4 2025; TTM through Dec 2025 was 38550000.0, a 152.15% decrease from a year earlier, with the FY2025 full-year figure at 38550000.0, down 152.19% from the prior year.
• Income from Continuing Operations for Q4 2025 stood at 4105000.0, up from 45117000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for SUPN reached as high as 38543000.0 in Q3 2024 and fell as low as 45117000.0 in Q3 2025.
• Historically, Income from Continuing Operations has averaged 7542750.0 across 5 years, with a median of 6779500.0 in 2021.
• Across the five-year window, Income from Continuing Operations jumped 2506.53% in 2024 and slumped 8370.63% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 2442000.0 in 2021, then surged by 944.55% to 25508000.0 in 2022, then sank by 95.39% to 1175000.0 in 2023, then soared by 1204.51% to 15328000.0 in 2024, then sank by 126.78% to 4105000.0 in 2025.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 4105000.0 in Q4 2025, 45117000.0 in Q3 2025, and 22499000.0 in Q2 2025.